Enveda Biosciences
Uses AI to decode nature for drug discovery.
Company facts
- Founded
- 2019
- Employees
- 325
- Headquarters
- United States
- CEO
- Viswa Colluru, PhD
- Type
- Private
- Funding
- Series D · $150M · 2025
- Subsidiaries
- Enveda Therapeutics India Pvt Ltd
About
Enveda Biosciences is revolutionizing drug discovery by harnessing the vast potential of nature's chemistry. Founded in 2019, the company operates at the intersection of biotechnology and artificial intelligence, utilizing a proprietary platform that processes and analyzes natural compounds to unlock their therapeutic potential. Enveda's innovative approach allows for the exploration of the chemical biodiversity contained within the natural world, which has previously been largely untapped by modern science. At the core of Enveda's mission is the desire to accelerate the discovery of better medicines, providing hope to millions of patients globally. By focusing on naturally occurring substances, the company aims to expedite therapeutics that are not only effective but can also be developed more sustainably compared to traditional synthetic drugs. Enveda employs cutting-edge machine learning tools to identify and characterize a plethora of molecules sourced from plants and other organisms, ultimately translating ancient medicinal practices into modern healthcare solutions. This fusion of traditional knowledge with advanced technology positions Enveda as a leader in the rapidly evolving field of natural product drug discovery.
Open positions
Sr. CMC Project Manager
Let’s build the future of medicine - together. Remote | Full-Time | $135,000 - $150,000 YOUR ROLE As a Senior CMC Project Manager at Enveda, you'll own portfolio-level planning and execution of CMC development for our…
Sr. ADME and Quantitative Pharmacology Director
Let’s build the future of medicine - together. Join Enveda as a Sr. ADME and Quantitative Pharmacology Director and help us transform natural compounds into life-changing medicines. We’re a team driven by curiosity and…